IP Library Granted Patent US 9,782,434
Granted Patent B2
US 9,782,434 · App. 14/793,649 · Granted Oct 10, 2017

Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

Inventors: Hojabr Alimi (Santa Rosa, CA); Andrés Gutiérrez (Petaluma, CA)
Assignee: Sonoma Pharmaceuticals, Inc.
A61K33/20A61K33/00A61K33/40A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,434
App. No.
14/793,649
Granted
Oct 10, 2017
Kind
B2
Abstract

Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.

Claims (13)

1. A method of treating atopic dermatitis in a patient, the method comprising administering to the patient a therapeutically effective amount of an oxidative reductive potential water solution, wherein the solution is stable for at least two months and the solution has a pH of from about 6.4 to about 7.8, wherein the oxidative reductive potential water solution comprises a mixture of cathode water and anode water, wherein the oxidative reductive potential water solution comprises free chlorine species at a level of about 10 ppm to about 400 ppm, wherein the free chlorine species is selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, dissolved chlorine gas, and mixtures thereof, wherein the oxidative reductive potential water solution inhibits mast cell degranulation, thereby treating the atopic dermatitis wherein the oxidative reductive potential water solution does not contain an antibiotic.

2. The method of claim 1 , wherein the oxidative reductive potential water solution is administered topically to cutaneous tissue or subcutaneous tissue.

3. The method of claim 1 , wherein the oxidative reductive potential water solution is administered as a liquid, steam, aerosol, mist or spray.

4. The method of claim 1 , wherein the oxidative reductive potential water solution is administered by aerosolization, nebulization or atomization.

5. The method of claim 1 , wherein the atopic dermatitis is caused by an autoimmune reaction.

6. The method of claim 1 , wherein the atopic dermatitis is caused by an infection.

7. The method of claim 6 , wherein the infection is by one or more microorganisms selected from the group consisting of viruses, bacteria, and fungi.

8. The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least six months.

9. The method of claim 1 , wherein the oxidative reductive potential water solution is stable for at least one year.

10. The method of claim 1 , wherein the pH of the oxidative reductive potential water solution is from about 7.4 to about 7.6.

11. The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 10% by volume to about 50% by volume of cathode water and from about 50% by volume to about 90% by volume of anode water.

12. The method of claim 1 , wherein the oxidative reductive potential water solution comprises from about 15 ppm to about 35 ppm hypochlorous acid, from about 25 ppm to about 50 ppm sodium hypochlorite, a pH of from about 6.2 to about 7.8, and the solution is stable for at least two months.

13. The method of claim 1 , wherein the oxidative reductive potential water solution has a potential between about −400 mV and about +1300 mV.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: SONOMA PHARMACEUTICALS, INC.
To: MICROSAFE GROUP DMCC
Reel/Frame 054084/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2017
From: ALIMI, HOJABR; GUTIERREZ, ANDRES
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 043530/0554 →
CHANGE OF NAME Recorded Jan 5, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 041257/0375 →
Continuity (7)
Continuation 12643191 · Dec 21, 2009
Continuation 11656087 · Jan 22, 2007
Provisional Application 60760635 · Jan 20, 2006
Provisional Application 60760567 · Jan 20, 2006
Provisional Application 60760645 · Jan 20, 2006
Provisional Application 60760557 · Jan 20, 2006
Related Publication 20150306137A1 · Oct 29, 2015